Abstract: Video messaging systems and methods utilize a video messaging component based on a video messaging component container stored in a data store. The video messaging component container includes a collaborative video list that shows a list of video content generated by users of the video messaging component. Iterations of the video messaging component are rendered in host applications on client devices. As video content is generated by the iterations, the collaborative video list is updated to include the video content, and the iterations of the video messaging component are updated to reflect changes to the collaborative video list in real-time.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present disclosure relates to a video presentation method and apparatus, and an electronic device and a storage medium. The method includes: presenting an associated-video recommendation entry in a video playing interface where a first video is presented; and in response to a trigger operation on the associated-video recommendation entry, presenting the video playing interface and an extension panel, wherein the extension panel comprises at least one recommended-video card, the recommended-video card is used for presenting related information of a recommended video, and the recommended video has an association relationship with the first video, and the video playing interface is configured to play the video recommended by the recommended-video card.

Abstract: The present disclosure relates to a microneedle having a responsive hydrogel disposed therein. The responsive hydrogel can include optically active particles and capture agents. In particular, such a microneedle can be provided within a device or a monitoring system. Methods of using such microneedles are provided, such as for detection of an analyte.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: Video messaging systems and methods utilize a video messaging component based on a video messaging component container stored in a data store. The video messaging component container includes a collaborative video list that shows a list of video content generated by users of the video messaging component. Iterations of the video messaging component are rendered in host applications on client devices. As video content is generated by the iterations, the collaborative video list is updated to include the video content, and the iterations of the video messaging component are updated to reflect changes to the collaborative video list in real-time.

Abstract: The disclosure provides a novel method for treating genetic disorders where a peptide sequence targets proteins produced via gene therapy into exosomes. These protein-loaded exosomes can enter into non-transduced cells and correct pathology. Also, gene therapy compositions, protein replacement therapy composition, pharmaceutical compositions, methods of treatment, and uses of the gene therapy compositions and the recombinant proteins are also disclosed. The method can also be used to improve in vitro recombinant protein yield.

Abstract: Physiologically-tailored tissue organoids are disclosed for monitoring and treating diseases and improving an individual's health.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: A flapping-wing aerial robot formation control method includes: determining a trailing vortex generation mechanism, an energy saving principle and a trailing vortex attenuation mechanism of the formation flight of a group of wild geese in accordance with the pattern of the formation flight of the group of wild geese; determining the formation flight of a group of flapping-wing aerial robots and a formation switching solution in accordance with the trailing vortex generation mechanism, energy saving principle and trailing vortex attenuation mechanism of the formation flight of the group of wild geese in conjunction with the flapping characteristic of a flapping-wing aerial robot from the perspective of energy consumption equalization and energy saving; and carrying out formation keeping control and formation reconfiguration control in accordance with the formation flight of the group of flapping-wing aerial robots and the formation switching solution by controlling positions of the group of flapping-wing aeria

Abstract: A flapping-wing aerial robot formation control method includes: determining a trailing vortex generation mechanism, an energy saving principle and a trailing vortex attenuation mechanism of the formation flight of a group of wild geese in accordance with the pattern of the formation flight of the group of wild geese; determining the formation flight of a group of flapping-wing aerial robots and a formation switching solution in accordance with the trailing vortex generation mechanism, energy saving principle and trailing vortex attenuation mechanism of the formation flight of the group of wild geese in conjunction with the flapping characteristic of a flapping-wing aerial robot from the perspective of energy consumption equalization and energy saving; and carrying out formation keeping control and formation reconfiguration control in accordance with the formation flight of the group of flapping-wing aerial robots and the formation switching solution by controlling positions of the group of flapping-wing aeria

Abstract: Methods and compositions for preventing or inhibiting the formation of scars are disclosed. The methods and compositions include a TGF-? inhibitor provided in a delayed release composition.

Abstract: Compositions and methods are provided concerning a lactate-responsive drug release system. In some embodiments, there are methods and compositions for treating cancer that take advantage of the tumor environment to deliver therapeutic agents to the tumor while reducing problems associated with circulating drugs in the patients body.

Abstract: Embodiments of the present application provide a method, apparatus, and electronic device for eliminating distortion of a distorted image. Side information components of a distorted image are generated. The distorted image is resulted from image processing on an original image. Side information components represent distortion features of the distorted image with respect to original image. Distorted image color components of the distorted image and the side information components are input into a pre-established convolutional neural network model for convolution filtering to obtain distortion-eliminated image color components. The convolutional neural network model is obtained through training based on a preset training set. The training set comprises original sample images, distorted image color components of multiple distorted images corresponding to each of the original sample images, and side information components of each of the distorted images.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: Embodiments of the present application provide a method, apparatus, and electronic device for eliminating distortion of a distorted image. Side information components of a distorted image are generated. The distorted image is resulted from image processing on an original image. Side information components represent distortion features of the distorted image with respect to original image. Distorted image color components of the distorted image and the side information components are input into a pre-established convolutional neural network model for convolution filtering to obtain distortion-eliminated image color components. The convolutional neural network model is obtained through training based on a preset training set. The training set comprises original sample images, distorted image color components of multiple distorted images corresponding to each of the original sample images, and side information components of each of the distorted images.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.